drugset / Trial / NCT04164732

Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy

NCT04164732

Phase 2 Completed 46 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study was to determine if LCZ696 can improve functional capacity (via improved peak VO2) in non-obstructive hypertrophic cardiomyopathy (HCM) patient population over the course of 50 weeks of treatment.

Timeline

Start
2020-01-08
Primary completion
2023-08-22
Completion
2023-08-22

Drugs

EvaluationDrugModalityDoseRoute
Subject Sacubitril Small molecule Oral
Subject Valsartan Small molecule Oral

Indications

No indication recorded.